Skip to content
DataLookout
Menu

NCT07226661

Double-blind, Placebo-controlled Study in Adults With Major Depressive Disorder

StatusRecruiting
PhasePhase 2
Primary completion (estimated)
Track this trial

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Record History

All 4 versions: 3 with changes below, 1 re-verified with no change. See every version on ClinicalTrials.gov ↗

  1. Notable Eligibility criteria expanded, about 14 words
    • Trial sites expanded: 1 → 40 locations
    • Secondary endpoints: details revised at 1 of 1 entry
  2. Notable Trial status: Not Yet Recruiting to Recruiting
    • Start date changed from estimate of Jan 1, 2026 to Jan 19, 2026
    • Site details revised
    v2
  3. Study First Submitted
  • Notable: the plan changed

Endpoints

Primary

Change From Baseline to Day 29 in the Montgomery-Åsberg Depression Rating Scale (MADRS) Total Score.
Timeframe: 4 weeks

Secondary (1)

Change From Baseline to Day 29 in the Clinical Global Impression - Severity of Illness Score (CGI-S).

Arms and interventions

SPN-821 2400 mgExperimental

Three 800 mg oral tablets administered twice a week adjunctive to current antidepressant

PlaceboPlacebo comparator

Three oral tablets administered twice a week adjunctive to current antidepressant

Drugs: SPN-821 2400 mg, Placebo

Sites

40 sites in 1 country